Issue: 2020 > February > case report

Viral encephalitis associated with rituximab maintenance therapy: two cases and a review of literature

D.P. Noij, T. den Heijer, H.C.T. van Zaanen
AbstractFull textPDF


Rituximab is increasingly used in the treatment of CD20-positive B-cell-mediated disease. Prolonged use may cause B-cell dysfunction, dose-dependent T-cell dysfunction, and hypogammaglobulinaemia and result in severe non-neutropenic infections. We present two cases of viral encephalitis in patients treated with rituximab maintenance therapy: one patient presented with deafness; the other patient with paroxysmal light flashes, apraxia, and weakness.